This technology includes a new class of nanobody–antiviral peptide conjugates that block HIV from infecting human CD4⁺ T-cells, positioning them for future therapeutic and prophylactic use. Nanobodies—single-domain antibody fragments—guide the drug to the virus’s docking site and impede receptor binding, while the linked peptide halts the membrane-fusion step, creating a one-two punch against viral entry. In cell-based infection assays the conjugates are markedly more potent than either the peptide alone or a widely used broadly neutralizing anti-HIV antibody, enabling lower dosing and reduced systemic toxicity. Because the construct strikes two independent stages of the viral life-cycle, it raises the genetic barrier to resistance that limits existing treatments. The modular chemistry also allows rapid retargeting to emerging HIV strains or other enveloped viruses.